No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.
Identifieur interne : 000424 ( Main/Exploration ); précédent : 000423; suivant : 000425No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.
Auteurs : Salaheddin M. Mahmud [Canada] ; Paul Van Caeseele ; Gregory Hammond ; Carol Kurbis ; Tim Hilderman ; Lawrence ElliottSource :
- Emerging infectious diseases [ 1080-6059 ] ; 2012.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (), Grippe humaine (épidémiologie), Humains, Jeune adulte, Manitoba (épidémiologie), Mâle, Nourrisson, Pandémies, Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé, Vaccins antigrippaux (administration et posologie), Études cas-témoins.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A.
- épidémiologie : Grippe humaine, Manitoba.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Nourrisson, Pandémies, Sujet âgé, Études cas-témoins.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Manitoba (epidemiology), Middle Aged, Pandemics, Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Manitoba.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Pandemics, Young Adult.
Abstract
We conducted a population-based study in Manitoba, Canada, to investigate whether use of inactivated trivalent influenza vaccine (TIV) during the 2008-09 influenza season was associated with subsequent infection with influenza A(H1N1)pdm09 virus during the first wave of the 2009 pandemic. Data were obtained from a provincewide population-based immunization registry and laboratory-based influenza surveillance system. The test-negative case-control study included 831 case-patients with confirmed influenza A(H1N1)pdm09 virus infection and 2,479 controls, participants with test results negative for influenza A and B viruses. For the association of TIV receipt with influenza A(H1N1)pdm09 virus infection, the fully adjusted odds ratio was 1.0 (95% CI 0.7-1.4). Among case-patients, receipt of 2008-09 TIV was associated with a statistically nonsignificant 49% reduction in risk for hospitalization. In agreement with study findings outside Canada, our study in Manitoba indicates that the 2008-09 TIV neither increased nor decreased the risk for infection with influenza A(H1N1)pdm09 virus.
DOI: 10.3201/eid1805.111596
PubMed: 22516189
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.</title>
<author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Manitoba, Winnipeg, Manitoba, Canada. salah.mahmud@gmail.com</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Manitoba, Winnipeg, Manitoba</wicri:regionArea>
<orgName type="university">Université du Manitoba</orgName>
<placeName><settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name>
</author>
<author><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name>
</author>
<author><name sortKey="Kurbis, Carol" sort="Kurbis, Carol" uniqKey="Kurbis C" first="Carol" last="Kurbis">Carol Kurbis</name>
</author>
<author><name sortKey="Hilderman, Tim" sort="Hilderman, Tim" uniqKey="Hilderman T" first="Tim" last="Hilderman">Tim Hilderman</name>
</author>
<author><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22516189</idno>
<idno type="pmid">22516189</idno>
<idno type="doi">10.3201/eid1805.111596</idno>
<idno type="wicri:Area/Main/Corpus">000442</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000442</idno>
<idno type="wicri:Area/Main/Curation">000442</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000442</idno>
<idno type="wicri:Area/Main/Exploration">000442</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.</title>
<author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Manitoba, Winnipeg, Manitoba, Canada. salah.mahmud@gmail.com</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Manitoba, Winnipeg, Manitoba</wicri:regionArea>
<orgName type="university">Université du Manitoba</orgName>
<placeName><settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name>
</author>
<author><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name>
</author>
<author><name sortKey="Kurbis, Carol" sort="Kurbis, Carol" uniqKey="Kurbis C" first="Carol" last="Kurbis">Carol Kurbis</name>
</author>
<author><name sortKey="Hilderman, Tim" sort="Hilderman, Tim" uniqKey="Hilderman T" first="Tim" last="Hilderman">Tim Hilderman</name>
</author>
<author><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="eISSN">1080-6059</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male</term>
<term>Manitoba (epidemiology)</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Manitoba (épidémiologie)</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Pandémies</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Manitoba</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Manitoba</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We conducted a population-based study in Manitoba, Canada, to investigate whether use of inactivated trivalent influenza vaccine (TIV) during the 2008-09 influenza season was associated with subsequent infection with influenza A(H1N1)pdm09 virus during the first wave of the 2009 pandemic. Data were obtained from a provincewide population-based immunization registry and laboratory-based influenza surveillance system. The test-negative case-control study included 831 case-patients with confirmed influenza A(H1N1)pdm09 virus infection and 2,479 controls, participants with test results negative for influenza A and B viruses. For the association of TIV receipt with influenza A(H1N1)pdm09 virus infection, the fully adjusted odds ratio was 1.0 (95% CI 0.7-1.4). Among case-patients, receipt of 2008-09 TIV was associated with a statistically nonsignificant 49% reduction in risk for hospitalization. In agreement with study findings outside Canada, our study in Manitoba indicates that the 2008-09 TIV neither increased nor decreased the risk for infection with influenza A(H1N1)pdm09 virus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22516189</PMID>
<DateCompleted><Year>2013</Year>
<Month>01</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1080-6059</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>5</Issue>
<PubDate><Year>2012</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009.</ArticleTitle>
<Pagination><MedlinePgn>801-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3201/eid1805.111596</ELocationID>
<Abstract><AbstractText>We conducted a population-based study in Manitoba, Canada, to investigate whether use of inactivated trivalent influenza vaccine (TIV) during the 2008-09 influenza season was associated with subsequent infection with influenza A(H1N1)pdm09 virus during the first wave of the 2009 pandemic. Data were obtained from a provincewide population-based immunization registry and laboratory-based influenza surveillance system. The test-negative case-control study included 831 case-patients with confirmed influenza A(H1N1)pdm09 virus infection and 2,479 controls, participants with test results negative for influenza A and B viruses. For the association of TIV receipt with influenza A(H1N1)pdm09 virus infection, the fully adjusted odds ratio was 1.0 (95% CI 0.7-1.4). Among case-patients, receipt of 2008-09 TIV was associated with a statistically nonsignificant 49% reduction in risk for hospitalization. In agreement with study findings outside Canada, our study in Manitoba indicates that the 2008-09 TIV neither increased nor decreased the risk for infection with influenza A(H1N1)pdm09 virus.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmud</LastName>
<ForeName>Salaheddin M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>University of Manitoba, Winnipeg, Manitoba, Canada. salah.mahmud@gmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Caeseele</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hammond</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kurbis</LastName>
<ForeName>Carol</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hilderman</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Elliott</LastName>
<ForeName>Lawrence</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N" Type="Geographic">Manitoba</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>1</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22516189</ArticleId>
<ArticleId IdType="doi">10.3201/eid1805.111596</ArticleId>
<ArticleId IdType="pmc">PMC3358049</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biometrics. 1988 Dec;44(4):1157-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3233252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):749-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15386720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Public Health. 1994 Oct;84(10):1666-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7943493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Care. 1997 Sep;35(9):932-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9298082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can Commun Dis Rep. 2008 Jul;34(ACS-3):1-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18802991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Jul 10;325(5937):197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19465683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2009;339:b3928</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19808768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Nov 13;58(44):1241-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19910912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2009;339:b4972</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19934198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Dec 15;49(12):1801-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19911946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Dec 15;49(12):1811-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19911964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2009 Dec;47(12):3805-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19794033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(12):e8431</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20037716</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Dec 31;361(27):2628-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20042754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2009 Dec 19;374(9707):2072-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19913290</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2010 Feb 23;182(3):257-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20093297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2010 Mar 6;375(9717):801-2; author reply 802-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20206765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2010 Mar 9;182(4):349-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20159893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2010 Apr;16(4):719-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20350398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2010 Apr;7(4):e1000258</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20386731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2010 Apr 14;303(14):1383-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20388894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(5):e10722</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20502705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Cell Biol. 2010 Aug;88(4):589-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20651829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010;15(28). pii: 19616</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20650055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 4;28(42):6852-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20723626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Nov 3;28(47):7460-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20875486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2010 Dec 15;51(12):1370-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21067351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2010 Dec 15;51(12):1380-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21067354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010 Nov 25;15(47). pii: 19722</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21144441</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gac Sanit. 2011 Jan-Feb;25(1):23-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21334788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Mar 21;29(14):2613-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21292008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Intern Med. 2011 May;26(5):546-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21203857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Aug 26;29(37):6419-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21473950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can J Public Health. 2002 Nov-Dec;93 Suppl 2:S15-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12580385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 1992 May 1;135(9):1019-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1595688</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Manitoba</li>
</region>
<settlement><li>Winnipeg</li>
</settlement>
<orgName><li>Université du Manitoba</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name>
<name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name>
<name sortKey="Hilderman, Tim" sort="Hilderman, Tim" uniqKey="Hilderman T" first="Tim" last="Hilderman">Tim Hilderman</name>
<name sortKey="Kurbis, Carol" sort="Kurbis, Carol" uniqKey="Kurbis C" first="Carol" last="Kurbis">Carol Kurbis</name>
<name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name>
</noCountry>
<country name="Canada"><region name="Manitoba"><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000424 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000424 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= GrippeCanadaV3 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:22516189 |texte= No association between 2008-09 influenza vaccine and influenza A(H1N1)pdm09 virus infection, Manitoba, Canada, 2009. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22516189" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a GrippeCanadaV3
This area was generated with Dilib version V0.6.35. |